<DOC>
	<DOCNO>NCT02768220</DOCNO>
	<brief_summary>Single-center open-label multiple dose randomized two period cross-over study examine Advanced Glycation End Product ( AGE ) level human subject pre post empagliflozin administration .</brief_summary>
	<brief_title>The Effect Sodium-Glucose Cotransporter 2 Inhibitors Advanced Glycation End Products</brief_title>
	<detailed_description>Single-center open-label multiple dose randomized two period cross-over study . The North-Shore Long Island Jewish Institutional Review Board use approve study protocol . All patient give write informed consent comply Helsinki agreement good clinical practice guideline . Treatment Plan : Eligible patient randomize receive linagliptin 5mg daily empagliflozin 25mg daily 30 day follow 30 day washout period crossover . All pre-existing diabetic medication continue unchanged . Fasting blood carboxymethyl lysine ( CML ) , methylglyoxal ( MG ) , vascular cell adhesion molecule ( VCAM ) , tumor necrosis factor ( TNF ) alpha , 8-isoprostane , routine chemistry urinary CML , MG , creatinine measure baseline , 30 day , 60 day 90 day . AGE level measure Elisa .</detailed_description>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>T2DM Age ≥ 18 glomerular filtration rate ≥ 30 ml/min/1.73 m2 bodysurface area A1C ≥ 7 % high limit SLGT2 inhibitor naïve On stable dos current medication least 3 month . Indication liver disease , define serum level alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase 2 x upper limit normal screen runin phase Blood dyscrasia disorder cause hemolysis unstable red blood cell Contraindications background therapy accord local label Any uncontrolled endocrine disorder except type 2 diabetes Premenopausal woman ( last menstruation ≤1 year prior informed consent ) nursing , pregnant , childbearing potential practicing acceptable method birth control , plan continue use method throughout study , agree submit periodic pregnancy test trial Acceptable method birth control include tubal ligation , transdermal patch , intrauterine devices/systems , oral , implantable injectable contraceptive , sexual abstinence , double barrier method , vasectomy partner Alcohol drug abuse within 3 month inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake Intake investigational drug another trial within 30 day prior intake study medication trial participate another trial involve investigational drug and/or followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>